nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2015-2-3-34-38nodgo-123Research ArticleАКТУАЛЬНЫЕ ВОПРОСЫ ТГСК У ДЕТЕЙ: PRO ET CONTRATOPICAL ISSUES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN: PRO ET CONTRAДеплеция альфа/бета-Т-лимфоцитов – надежная платформа для развития трансплантации гемопоэтических стволовых клеток от гаплоидентичных доноровDepletion of alpha/beta-T-cells is a robust platform for haploidentical hematopoietic stem cell transplantation results improvementМасчанМ. А.MaschanM. A.mmaschan@yandex.ruФГБУ «ФНКЦ ДГОИ им. Дмитрия Рогачева» Минздрава России; Россия, 117198, Москва, ул. Саморы Машела, 1РоссияFederal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, RussiaRussian Federation201529092015233438Copyright © Масчан М.А., 20152015Масчан М.А.Maschan M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/123

материале представлено мнение об эффективности деплеции альфа/бета-Т-лимфоцитов, как надежной платформе для развития трансплантации гемопоэтических стволовых клеток (ТГСК) от гаплоидентичных доноров. Представлены исторические аспекты разработки и оптимизации метода, а также преимущества данного вида деплеции на современном этапе. Показана эффективность деплеции альфа/бета-Т-лимфоцитов как способа значимой редукции опасности реакции «трансплантат против хозяина»и, следовательно, инфекционных осложнений. Материал представлен в формате «личное мнение» и отражает позицию руководителя отдела ТГСК ФНКЦ ДГОИ им. Дмитрия Рогачева.

An opinion on alpha/beta-T-cells depletion as effective platform for haploidentical hematopoietic stem cells transplantation (HSCT) is presented in this article. Historical aspects of the method development and improvement, advantages of this type of depletion in the modern era are presented. Effectiveness of alpha/beta-T-cell depletion for significant reduction of the risk of graft-versus-host disease and infection complications is showed. Article presented in the format of personal opinion of the head of department of the Dmitry Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology.

детигаплоидентичная трансплантация гемопоэтических стволовых клетокдетидеплецияреакция «трансплантат против хозяина»селекцияTCR альфа/бета лимфоцитыhaploidentical hematopoietic stem cell transplantationchildrendepletionreaction of graft-versus-host diseaseselectionTCR alpha/beta lymphocytesReferencesHo V.T., Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001;98(12):3192–204.Ho V.T., Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001;98(12):3192–204.Leung W., Campana D., Yang J. et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011;118(2):223–30.Leung W., Campana D., Yang J. et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011;118(2):223–30.Booth C., Lawson S., Veys P. The current role of T cell depletion in paediatric stem cell transplantation. Brit J Haematol 2013;162(2):177–90.Booth C., Lawson S., Veys P. The current role of T cell depletion in paediatric stem cell transplantation. Brit J Haematol 2013;162(2):177–90.Aversa F., Tabilio A., Velardi A. et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998;339(17):1186–93.Aversa F., Tabilio A., Velardi A. et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998;339(17):1186–93.Schumm M., Lang P., Bethge W. et al. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy 2013;15(10):1253–8.Schumm M., Lang P., Bethge W. et al. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy 2013;15(10):1253–8.Chaleff S., Otto M., Barfield R.C. et al. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy 2007;9(8):746–54.Chaleff S., Otto M., Barfield R.C. et al. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy 2007;9(8):746–54.Handgretinger R. New approaches to graft engineering for haploidentical bone marrow transplantation. Semin Oncol 2012;39(6):664–73.Handgretinger R. New approaches to graft engineering for haploidentical bone marrow transplantation. Semin Oncol 2012;39(6):664–73.Bertaina A., Merli P., Rutella S. et al. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. Blood 2014;124(5):822–6.Bertaina A., Merli P., Rutella S. et al. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. Blood 2014;124(5):822–6.Lang P., Feuchtinger T., Teltschik H.M. et al. Improved immune recovery after transplantation of TCRalphabeta/CD19- depleted allografts from haploidentical donors in pediatric patients. Bone Marrow Transplant 2015;50 Suppl 2:S6–10.Lang P., Feuchtinger T., Teltschik H.M. et al. Improved immune recovery after transplantation of TCRalphabeta/CD19- depleted allografts from haploidentical donors in pediatric patients. Bone Marrow Transplant 2015;50 Suppl 2:S6–10.Handgretinger R., Schumm M., Lang P. et al. Transplantation of megadoses of purified haploidentical stem cells. Ann N Y Acad Sci 1999;872:351–61; discussion 361–2.Handgretinger R., Schumm M., Lang P. et al. Transplantation of megadoses of purified haploidentical stem cells. Ann N Y Acad Sci 1999;872:351–61; discussion 361–2.Eyrich M., Leiler C., Lang P. et al. A prospective comparison of immune reconstitution in pediatric recipients of positively selected CD34+ peripheral blood stem cells from unrelated donors vs recipients of unmanipulated bone marrow from related donors. Bone Marrow Transplant 2003;32(4):379–90.Eyrich M., Leiler C., Lang P. et al. A prospective comparison of immune reconstitution in pediatric recipients of positively selected CD34+ peripheral blood stem cells from unrelated donors vs recipients of unmanipulated bone marrow from related donors. Bone Marrow Transplant 2003;32(4):379–90.Passweg J.R., Baldomero H., Bader P. et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant 2015;50(4):476–82.Passweg J.R., Baldomero H., Bader P. et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant 2015;50(4):476–82.Lankester A.C., Locatelli F., Bader P. et al. Will post-transplantation cell therapies for pediatric patients become standard of care? Biol Blood Marrow Transplant 2015;21(3):402–11.Lankester A.C., Locatelli F., Bader P. et al. Will post-transplantation cell therapies for pediatric patients become standard of care? Biol Blood Marrow Transplant 2015;21(3):402–11.

The authors declare that there are no conflicts of interest present.